134 related articles for article (PubMed ID: 36750426)
1. Comparison of faecal calprotectin using two collection and extraction strategies for the BÜHLMANN CALEX® Cap - possible implications for clinical cut-offs?
Bruce H; Osypiw J; Prajapati-Jha G; O'Driscoll S; Brealey M; Benton SC
Ann Clin Biochem; 2023 Jul; 60(4):236-242. PubMed ID: 36750426
[TBL] [Abstract][Full Text] [Related]
2. BÜHLMANN Calex® Cap for the faecal extraction of calprotectin - Fit for purpose?
Kaur S; Ford C; Gama R
Ann Clin Biochem; 2020 Jul; 57(4):332-333. PubMed ID: 32429682
[No Abstract] [Full Text] [Related]
3. Reference Intervals for Fecal Calprotectin in Adults Using Two Different Extraction Methods in the Uppsala-SCAPIS Cohort.
Fall T; Mandic-Havelka A; Helmersson-Karlqvist J; Sundstrom J; Larsson A
Clin Lab; 2017 Sep; 63(9):1493-1496. PubMed ID: 28879709
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within- and between-method variability.
Juricic G; Brencic T; Tesija-Kuna A; Njegovan M; Honovic L
Biochem Med (Zagreb); 2019 Feb; 29(1):010707. PubMed ID: 30799976
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA.
O'Driscoll S; Piggott C; Benton SC
Clin Chem Lab Med; 2022 May; 60(6):901-906. PubMed ID: 35285587
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
7. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
8. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children.
Sandhu K; Naik S; Ayling RM
Ann Clin Biochem; 2021 May; 58(3):230-235. PubMed ID: 33412889
[TBL] [Abstract][Full Text] [Related]
9. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods.
Pelkmans LPJ; de Groot MJM; Curvers J
Am J Clin Pathol; 2019 Aug; 152(3):392-398. PubMed ID: 31152542
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method.
Coorevits L; Baert FJ; Vanpoucke HJ
Clin Chem Lab Med; 2013 Apr; 51(4):825-31. PubMed ID: 23001318
[TBL] [Abstract][Full Text] [Related]
12. [Faecal calprotectin is a useful biomarker for intestinal inflammation].
Theede K; Kiszka-Kanowitz M; Nordgaard-Lassen I; Nielsen AM
Ugeskr Laeger; 2014 Sep; 176(37):. PubMed ID: 25294035
[TBL] [Abstract][Full Text] [Related]
13. Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods.
Kristensen V; Lauritzen T; Jelsness-JØrgensen LP; Moum B
Scand J Clin Lab Invest; 2015 Sep; 75(5):355-61. PubMed ID: 25856663
[TBL] [Abstract][Full Text] [Related]
14. Patient-performed extraction of faecal calprotectin.
Kristensen V; Lauritzen T; Jelsness-Jørgensen LP; Frigstad SO; Corwin C; Moum B
Clin Chem Lab Med; 2016 Aug; 54(8):1357-63. PubMed ID: 26812797
[TBL] [Abstract][Full Text] [Related]
15. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.
Mowat C; Digby J; Strachan JA; Wilson R; Carey FA; Fraser CG; Steele RJ
Gut; 2016 Sep; 65(9):1463-9. PubMed ID: 26294695
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.
Delefortrie Q; Schatt P; Grimmelprez A; Gohy P; Deltour D; Collard G; Vankerkhoven P
Clin Biochem; 2016 Feb; 49(3):268-73. PubMed ID: 26506117
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
18. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.
van Rheenen PF; Van de Vijver E; Fidler V
BMJ; 2010 Jul; 341():c3369. PubMed ID: 20634346
[TBL] [Abstract][Full Text] [Related]
19. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.
Kittanakom S; Shajib MS; Garvie K; Turner J; Brooks D; Odeh S; Issenman R; Chetty VT; Macri J; Khan WI
Can J Gastroenterol Hepatol; 2017; 2017():1450970. PubMed ID: 28491862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
